Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250621 | 1.00 | KCNA5 (0.51) | KCNA5CHRM4MAPK1TP53MAPT | |
| SCHEMBL2247550 | 0.90 | CHRM4 (0.49) | KCNA5CHRM4MAPK1TP53MAPT | |
| SCHEMBL2248028 | 0.84 | CHRM2 (0.55) | CHRM4CHRM2 | |
| SCHEMBL2547214 | 0.80 | KCNA5 (0.51) | KCNA5CHRM4MAPK1MAPTALOX15 | |
| SCHEMBL2249060 | 0.80 | KCNA5 (0.51) | KCNA5CHRM4MAPK1MAPTALOX15 | |
| SCHEMBL1825906 | 0.75 | PTPN1 (0.50) | FPR2 | |
| SCHEMBL1825908 | 0.75 | PTPN1 (0.50) | FPR2 | |
| SCHEMBL2243961 | 0.75 | CHRM2 (0.55) | CHRM4CHRM2 | |
| SCHEMBL8271444 | 0.75 | CHRM2 (0.55) | CHRM4CHRM2 | |
| SCHEMBL9104053 | 0.74 | KCNA5 (0.62) | KCNA5CHRM4MAPK1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | KCNA5 3352/4885CHRM4 1379/4885MAPK1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.